InnoPharma is a sterile product development company focused on complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Its pipeline comprises a broad portfolio of products under development with formulations including solutions, suspensions, lyophilized products, emulsions, liposomes, micelles and lipid complexes. The company targets small molecules with solubility and stability challenges as well as difficult-to-produce and characterize polypeptides and carbohydrates. InnoPharma operates state-of-the-art R&D facilities in New Jersey with capabilities to handle potent and cytotoxic molecules. The $20 million term loan closed with Athyrium Capital Management is intended to provide greater financial flexibility to grow and expand its product portfolio. Management indicated the financing will support ongoing product development and longer-term results. InnoPharma is a sterile product development company focused on niche generic and innovative specialty pharmaceutical products. The company develops injectable and ophthalmic dosage forms and intends to use recent financing proceeds to advance those programs. Its portfolio under development includes formulations such as solutions, suspensions, lyophilized products, emulsions, liposomes, micelles and lipid complexes. The pipeline targets small molecules with solubility and stability challenges as well as difficult-to-produce and -characterize polypeptides and carbohydrates. The company is led by president & CEO Navneet Puri, Ph.D. In July 2012 InnoPharma closed financing to support ongoing product development. InnoPharma develops sterile generic and specialty pharmaceutical products, with capabilities for injectable and ophthalmic formulations at its Piscataway, New Jersey facilities. The company maintains a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products and partners with manufacturing and clinical research organizations worldwide for commercialization. Led by Founder, President, and CEO Navneet Puri, Ph.D., InnoPharma focuses on advancing its product pipeline. It completed a $15M Series A round of private financing to support those development efforts. As part of the corporate governance team, the board includes Navneet Puri, Raman Kapur (former CEO of Warrick Pharmaceuticals), and Peter Werth (CEO of ChemWerth).

Total raised

$43M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Nov 2013